deaths (OS)

mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive

versus Standard of Care (SoC)
atezolizumab alone vs. Standard of Care (SoC) 3 1.0better0.35.093 %
cemiplimab vs. Standard of Care (SoC) 1 1.0better0.35.0100 %
durvalumab alone vs. Standard of Care (SoC) 1 1.0better0.35.096 %
nivolumab alone vs. Standard of Care (SoC) 2 1.0better0.35.073 %
pembrolizumab alone vs. Standard of Care (SoC) 4 1.0better0.35.099 %